Literature DB >> 2220729

Factors influencing the development of metabolic bone disease in primary biliary cirrhosis.

N Guañabens1, A Parés, L Mariñoso, M A Brancós, C Piera, S Serrano, F Rivera, J Rodés.   

Abstract

The prevalence, type, and factors that may influence the development of bone disease in primary biliary cirrhosis, have been investigated in 20 consecutive patients, who, in addition to liver function tests and mineral and vitamin D metabolism studies, were submitted to a transiliac bone biopsy after tetracycline double-labeling for quantitative histomorphometric examination. Intestinal calcium absorption was also assessed in 16 patients. Seven patients (35%) had reduced bone volume and were considered osteoporotic. Three also had bone mineralization impairment, but did not have criteria for osteomalacia. Bone formation was depressed in 15 patients, and bone resorption was low or normal in 19 cases. Eroded surfaces were reduced in all osteoporotic patients. Duration of primary biliary cirrhosis was significantly longer in patients with osteoporosis (6.3 +/- 0.6 yr) than in those without osteoporosis (2.6 +/- 0.6, p = 0.004). Moreover, osteoporosis was more prevalent in postmenopausal women, and in those who had intestinal calcium malabsorption, which was present in 80% of osteoporotic patients but in only 18% of nonosteoporotic patients (p = 0.03). Osteoporosis and mineralization bone impairment were unrelated to the severity of cholestasis. 25-Hydroxyvitamin D was significantly lower in those patients with intestinal calcium malabsorption. The results of this study indicate that osteodystrophy in primary biliary cirrhosis is characterized mainly by "low-turnover" osteoporosis, which is related to the duration of the liver disease, postmenopausal condition, and calcium malabsorption.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2220729

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

1.  Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors:  Jane D Collier; M Ninkovic; J E Compston
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 2.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

3.  Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases.

Authors:  Karam A Mahdy; Hanaa H Ahmed; Fathia Mannaa; Azza Abdel-Shaheed
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

4.  Hepatic osteodystrophy and liver cirrhosis.

Authors:  Vedat Goral; Mehmet Simsek; Nuriye Mete
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

5.  Effect of liver dysfunction on circulating sclerostin.

Authors:  Yumie Rhee; Won Jin Kim; Ki Jun Han; Sung Kil Lim; Se Hwa Kim
Journal:  J Bone Miner Metab       Date:  2013-10-15       Impact factor: 2.626

Review 6.  Bone disease after liver transplantation.

Authors:  M S Losowsky; S H Hussaini
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

Review 7.  Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

8.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

Review 9.  Metabolic bone disease in patients with liver disease.

Authors:  Elizabeth Carey; Vijayan Balan
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 10.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.